ETFs Are Net Sellers of Revvity (RVTY) on Nov. 4
Revvity (RVTY) saw $25.3M net ETF outflows on Nov. 4, driven by DFSV's $27M reduction. 25 ETFs bought while 7 sold, but sellers had larger positions. RVTY operates in healthcare diagnostics, with $16.8B market cap, $2.94B TTM revenue, and 56.28% YTD gain. P/E is 66.77, P/B 2.32, and P/S 5.75.
How this was made
The 30-second read
Why it matters
The net selling pressure may depress RVTY's price in the near term, especially if other large holders follow DFSV's lead.
Market read
ETF outflows can act as an early warning of weakening demand for a stock, potentially prompting short‑term traders to adjust positions.
What to watch
Potential upcoming earnings or product announcements could reverse the current selling pressure.
Background
ETF flow data is often used to gauge institutional sentiment toward a stock. A net outflow of $25 million is notable for a mid‑cap like RVTY.
Ticker impact
ETF activity on Nov. 4 showed a net outflow of $25.3 million from Revvity (RVTY), led by DFSV selling $27 million worth of shares.
downward pressure as the market prices in the ETF sell‑off
DFSV cut its stake by over 80%, accounting for the bulk of the $27 million reduction, indicating institutional sellers are reducing exposure.
Market effects
The outflow may signal broader caution in the healthcare diagnostics sector if other ETFs follow suit.
Limited to U.S. listed RVTY; no immediate regional spillover.
Minimal global impact; primarily a micro‑level ETF flow story.
Counterpoint
If the sell‑off is a short‑term technical correction, the dip could present a buying opportunity for long‑term investors.
Key entities
- ETFDFSV
Largest seller of RVTY on Nov. 4, cutting its stake by 81.66%.
- ETFSPY
Second‑largest seller, trimming 9,165 shares.
